C oronary artery disease and myocardial infarction (MI) cause significant mortality, morbidity, and economic burden. 1 Despite current medical and interventional therapies, myocardial tissue lost during MI is replaced by noncontractile scar followed by remodeling of the left ventricle (LV) and gradual progression to heart failure. Based on promising results from preclinical studies and clinical trials, a new therapeutic approach-transplantation of adult bone marrowderived cells (BMCs) for heart repair-has gained vigorous momentum over the past decade. However, although BMC injection resulted in significant improvement in LV function and structure in many studies, 2,3 these benefits were mixed or absent in several others. 4 -8 Although results from clinical trials and meta-analyses have documented that BMC transplantation is feasible and safe, 7 the efficacy of this approach for cardiac repair continues to remain unclear and controversial. In addition, the long-term persistence of benefits of BMC transplantation remains uncertain. 9 
Clinical Perspective on p 568
Because of the relatively small number of patients even in pooled data sets, 7, 10 satisfactory analysis of several key aspects of outcomes could not be achieved previously. These include the impact of BMC transplantation on long-term patient-important clinical outcomes and the persistence of benefits during prolonged follow-up. Although surrogate end points demonstrate benefit with BMC transplantation, 7 understanding the clinical impact of this new therapy on hard clinical 
Data Extraction
Three investigators (V.J., M.B., and A.S.) independently screened all titles and abstracts to identify studies that met the inclusion criteria and extracted relevant data using a standardized form. The outcome measures included changes in LV ejection fraction (LVEF), infarct size, LV end-systolic volume (LVESV), and LV end-diastolic volume (LVEDV). The clinical outcome measures included all-cause mortality, cardiac mortality, heart failure, stent thrombosis, in-stent restenosis, target vessel revascularization, cerebrovascular event, and ventricular arrhythmia. Data with the longest duration of follow-up were included for primary and secondary outcome measures. LV volumes were estimated from LV volume indexes when appropriate. Modes of imaging included echocardiography, cardiac magnetic resonance imaging (MRI), left ventriculography (LVG), radionuclide ventriculography, and single-photon emission computed tomography (SPECT) ( Table 1) . MRI and SPECT data were preferred over echocardiographic data for primary analysis when available. When multiple imaging modalities were used in 1 study, data by each modality were extracted to be included in subgroup analyses. Clinical trials with multiple publications with sequential follow-up durations or different outcomes were considered as 1 study. For studies with 2 intervention arms 12, 23, 24, 32, 48 that involved 2 different doses (low dose and high dose of BMCs) or different routes of administration (intracoronary and intramuscular), data were combined by the use of methods described in the Cochrane handbook. 49 
Quality Assessment
The quality of included randomized controlled studies (RCTs) was assessed by use of the criteria established by Juni et al, 50 and the AMI indicates acute myocardial infarction; BMC, bone marrow cells; BMMNC, bone marrow mononuclear cells; CABG, coronary artery bypass graft; CIHD, chronic ischemic heart disease; DES, drug-eluting stent; Echo, echocardiography; EF, ejection fraction; EPC, endothelial progenitor cell; HSA, human serum albumin; IC, intracoronary; IM, intramuscular; IS, infarct size; LVG, left ventriculography; MI, myocardial infarction; MRI, magnetic resonance imaging; MSC, mesenchymal stem cells; NA, not available; NR, not reported; PCI, percutaneous coronary intervention; PET, positron emission tomography; RCT, randomized controlled trial; RNV, radionuclide ventriculography; SPECT, single photon emission computed tomography; and Vol, left ventricular volume.
*The imaging modality used for primary outcomes assessment in our meta-analysis.
quality of cohort studies was assessed by use of the modified Newcastle-Ottawa Scale. 51 
Data Analysis
Statistical analyses were performed with Cochrane RevMan version 5, and results were expressed as weighted mean differences for continuous outcomes with 95% confidence intervals (CIs). Data were pooled by use of the DerSimonian-Laird random-effects model, but a fixed-effects model was also used to ensure the robustness of the model chosen and the susceptibility to outliers. Heterogeneity was analyzed with the I 2 statistic, with a significance level of ␣ϭ0.05. For the I 2 statistic, heterogeneity was defined as low (25%-50%), moderate (50%-75%), or high (Ͼ75%). We planned to conduct sensitivity analysis if significant heterogeneity was found (I 2 Ͼ50%) for any one of the outcomes. For studies that reported meanϮSD at baseline and follow-up but did not report the actual change (from baseline to follow-up) as meanϮSD, the change in SD was calculated with a standardized formula previously used to calculate changes in mean and standard deviation. 52 The Peto odds ratio (OR) was calculated for clinical outcomes (all-cause mortality, cardiac mortality, recurrent MI, stent thrombosis, heart failure, in-stent restenosis, target vessel revascularization, cerebrovascular event, and ventricular arrhythmias).
Subgroup Analysis and Sensitivity Analysis
Planned subgroup analyses were conducted based on (1) type of study design (RCT versus cohort study); (2) type of IHD (acute MI versus chronic IHD); (3) duration of follow-up; (4) baseline LVEF of Ͻ43% versus Ն43% (43% was the median LVEF at baseline in included studies) and Ͻ50% versus Ն50% (LVEF Ͻ50% represents LV dysfunction); (5) and the use of heparin in the final cellular suspension; (9) location of MI (anterior versus multiple areas); and (10) route of injection. Sensitivity analyses were conducted to explore heterogeneity (investigating the effects of route of injection, sample size in studies, median LVEF, and median number of BMCs injected).
Results

Search Results
The initial search retrieved 1724 reports, of which 1544 were excluded on the basis of the title and abstract. After the exclusion of 36 review articles and 5 reports of ongoing trials, full-text analysis was performed on 139 reports, of which 89 were excluded because of unrelated outcomes and the use of granulocyte colony-stimulating factor and circulating progenitor cells. The remaining 50 studies (36 RCTs and 14 cohort studies enrolling a total of 2625 patients) [2] [3] [4] [5] [6] 9, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] that reported changes in LVEF, infarct size, LVESV, or LVEDV in patients who underwent BMC transplantation compared with standard therapy were included in the final analysis ( Figure 1 ). Table 1 summarizes the characteristics of included studies. The median follow-up duration was 6 months (range, 3-60 months), and the median sample size was 39 patients (range, 10 -391 patients). The timing of BMC transplantation in patients with acute MI varied among the included studies (median, 6.7 days; range, 1 to 18.4 days), and the median number of BMCs injected was 100ϫ10 6 (range, 2ϫ10
Study Characteristics
). The median EF of patients at baseline was 43% (range, 21%-62%).
Study Quality
The quality metrics of included RCTs are shown in Table 2, and  Table 3 summarizes the quality of cohort studies. All cohort studies and at least 15 RCTs failed to blind participants and/or caregivers; 7 RCTs did not provide adequate information on blinding of participants and caregivers; and blinding of outcome assessors was unclear in at least 3 RCTs. The loss and adequacy of follow-up in the eligible studies are provided in Tables 2 and  3 . The follow-up was complete in most studies with shorter follow-up duration. In studies with longer follow-up, the percent of patients lost to follow-up was acceptable. The inter-reviewer agreement on these quality domains was Ͼ90%.
Cardiac Parameters
Compared with the standard treatment group, BMC transplantation improved LVEF by 3.96% (95% CI, 2.90 -5.02; PϽ0.00001; Figure 2 ), reduced infarct size by 4.03% (95% CI, Ϫ5.47 to Ϫ2.59; PϽ0.00001; Figure 3 ), reduced LVESV by 8.9 mL (95% CI, Ϫ11.5 to Ϫ6.25; PϽ0.00001; Figure 4 ), and reduced LVEDV by 5.23 mL (95% CI, Ϫ7.6 to Ϫ2.86; PϽ0.0001; Figure 5 ).
Persistence of Benefits During Long-Term Follow-Up
With analyses based on the duration of follow-up, the improvement in LVEF persisted for at least Ͼ24 months, and 
Subgroup Analysis
Subgroup analysis showed that improvements in LV function, scar size, and LV volumes were significant regardless of the type of IHD (acute MI versus chronic IHD), except that BMC transplantation produced a greater reduction in LVESV in patients with chronic IHD (Table 5 ). The benefits of BMC therapy were similar in patients with MI in any territory compared with those with anterior MI, although improvement in LVEDV was greater in the latter (Table 5 ). The impact of baseline LVEF was analyzed separately on the basis of the median LVEF (43%) and the presence of LV systolic dysfunction (LVEF Ͻ50%). Results from both analyses showed that recipients of BMC transplantation with lower LVEF at baseline experienced significantly greater improvement in LVESV and LVEDV, with no significant reduction in LVEDV in recipients with baseline LVEF Ն43% and Ն50% (Table 5 ). In patients with acute MI, BMC injection Ͻ7 days after acute MI and/or percutaneous coronary intervention produced similar improvements in EF, scar size, and LVESV compared with BMC injection between 7 and 30 days. The improvement in LVEDV was also significant when cells were injected at Ͻ7 days, whereas BMC injection between 7 and 30 days failed to reduce LVEDV (Table 5) . Analysis based on the median BMC number (100ϫ10 6 ) showed that injection of Ն100ϫ10 6 BMCs produced similar improvements in LVEF, scar size, and LVEDV compared with Ͻ100ϫ10 6 BMCs, whereas reduction in LVESV was significantly greater with Ͻ100ϫ10 6 BMCs. Additional analyses using progressively lower BMC numbers showed that injection of Ն40ϫ10 6 BMCs resulted in significant improvement in all 4 primary outcome measures (LVEF, scar size, LVESV, and LVEDV), whereas injection of Յ40ϫ10 BMCs did not show improvement in any outcome ( Table 5 ), indicating that 40ϫ10 6 BMCs may represent the cutoff below which BMCs fail to exert a majority of the desired benefits.
In terms of cell types, 36 studies used BMMNCs, 5 studies used BMCs, 6 studies used CD133 ϩ and/or CD34 ϩ cells, and 3 studies used mesenchymal stem cells and/or endothelial progenitor cells. Subgroup analysis showed that although BMMNC therapy improved LVEF, scar size, and LV volumes, the pooled effects of CD133 ϩ and/or CD34 ϩ cell therapy were not significantly different compared with control subjects (Table 5 ). The reduction in scar size with BMMNC therapy was significantly greater compared with CD133 ϩ /CD34 ϩ cells. Analysis based on the methods of cell preparation showed similar benefits in LVEF, scar size, and LVESV when cells were isolated with Lymphoprep compared with other Ficoll-based methods (Table 5 ). Further subgroup analysis comparing studies that used heparinized saline versus saline-based solutions without heparin in the final cell suspension showed greater improvement in LVEF and LVESV with heparinized saline, whereas improvements in scar size and LVEDV were comparable with both methods (Table 5) . In 26 studies, cells were injected on the same day as BM harvest, and in 9 studies, cells were injected by the next day (Table 1) . BMCs were cultured or cell injection was delayed for up to 48 hours in 4 studies, and the time frame was unclear in 11. Because information on storage condition, especially temperature during storage, was not available in the vast majority, subgroup analysis was not performed.
In terms of the route of injection, all patients with acute MI received intracoronary injection of BMCs. Therefore, the impact of intracoronary versus intramyocardial route of injection was analyzed in patients with chronic IHD. In these patients, the outcomes were not significantly different between the 2 routes of BMC administration (Table 5) . With regard to the design of included studies, the benefits remained significant when RCTs and cohort studies were analyzed separately (Figures 2-5 ), albeit with greater magnitudes in cohort studies compared with RCTs (Table 5) .
Impact of BMC Therapy on Survival and Clinical Outcomes
Compared with patients who received standard therapy, BMC-treated patients experienced significant decrease in all-cause mortality (OR, 0.39; 95% CI, 0.27-0. 55 (1) representativeness of the exposed cohort: A, truly representative of the average patient with ischemic heart disease; B, somewhat representative of the average patient with ischemic heart disease; C, selected group; and D, no description of the derivation of the cohort. (2) Selection of the nonexposed cohort: A, drawn from the same community as the exposed cohort; B, drawn from a different source; and C, no description of the derivation of the nonexposed cohort. (3) Ascertainment of exposure: A, secure record (eg, surgical records); B, structured interview; C, written self-report; and D, no description. (4) Demonstration that outcome of interest was not present at start of study: A, yes; B, no. Comparability: comparability of cohorts on the basis of the design or analysis: A, study controls for comorbidities; B, study controls for additional risk factors (such as age and severity of illness); and C, not done. Outcome: (1) assessment of outcome: A, independent blind assessment; B, record linkage; C, self-report; and D, no description. (2) Was follow-up long enough for outcomes to occur: A, yes; B, no. (3) Adequacy of follow-up of cohorts: A, complete follow-up, all subjects accounted for; B, subjects lost to follow-up unlikely to introduce bias (small number lost), follow-up rate Ͼ90%, or description provided of those lost; C, follow-up rate Յ90% and no description of those lost; and D, no statement. 0.34; 95% CI, 0.12-0.94; I 2 ϭ6%; Pϭ0.04; Table 6 ). There were trends toward a reduction in the incidence of heart failure (OR, 0.52; 95% CI, 0. in BMC-treated patients compared with control subjects (Table 6 ).
Imaging Modalities and Outcomes
Significant differences were noted when the mean changes in LVEF, infarct size, and LVESV were compared among studies that used echocardiography, SPECT, MRI, or LVG for outcomes assessment. Specifically, improvement in LVEF in BMC-treated patients was significant when echo- 
Total (95% CI)
Heterogeneity: Tau² = 9.68; Chi² = 261.58, df = 49 (P < 0.00001); I² = 81% Test for overall effect: Z = 7.31 (P < 0.00001) Test for subgroup differences: Chi² = 3.53, df = 1 (P = 0.06), I² = 71.7% cardiography or LVG was used and showed a trend toward improvement with SPECT, whereas the increase was insignificant with MRI (Table 7) . Infarct scar size reduction was significant with both SPECT and LVG but not with MRI (Table 7) . Importantly, reduction in LVESV was significant with all imaging modalities, although the magnitude varied, whereas reduction in LVEDV was significant by echocardiography and SPECT but not by MRI or LVG (Table 7) .
Sensitivity Analysis
Heterogeneity was explored by conducting sensitivity analysis based on the route of injection, sample size, median LVEF, and median number of BMCs injected. All clinical trials in patients with acute MI used the intracoronary route for BMC injection. Analysis based on the route of injection, median LVEF, and median number of BMCs did not explain the heterogeneity (Table 5 ). Analysis of studies based on sample size (Ͻ50 versus Ն50 patients) did not change the results and did not explain the heterogeneity.
Publication Bias
We drew funnel plots to seek evidence of publication bias. When inconsistency was high, the funnel plots were not interpretable; when, inconsistency was low, the funnel plots were inconclusive.
Discussion
Salient Findings
Our meta-analysis of pooled data from 2625 patients, the largest to date, demonstrates that adult BMC transplantation results in modest yet significant improvements in LVEF, infarct scar size, LVESV, and LVEDV. therapeutic standpoint and provide a strong basis for largescale clinical trials.
BMC Therapy Improves LV Function and Remodeling
The primary objectives of cell therapy are to improve LV structure and function and to ameliorate patient symptoms. In this regard, results from individual clinical trials have been discordant, with some trials showing improvement in diverse functional and clinical parameters with BMC transplantation and others failing to document significant benefits. Based on data from 2625 patients, the current results indicate that injection of BMCs in patients with IHD results in modest improvements in LVEF, infarct size, LVESV, and LVEDV. The improvement in LV systolic function is noteworthy because LVEF is an important prognostic factor in patients with acute myocardial ischemic injury. 71 It is also important to note that although the 3.96% increase in LVEF is not large, the other therapeutic options in these patients are able to offer only similar benefits. 72 In addition, BMC transplantation also improved postinfarct remodeling as evidenced by reduction in infarct scar size and LVEDV. These benefits may translate into superior long-term prognosis in these patients. The mechanisms underlying these benefits remain poorly understood at this time, although enhanced angiogenesis and reduction in apoptosis through paracrine effects of growth 
Total (95% CI)
Heterogeneity: Tau² = 37.02; Chi² = 188.32, df = 35 (P < 0.00001); I² = 81% Test for overall effect: Z = 6.56 (P < 0.00001) Test for subgroup differences: Chi² = 5.51, df = 1 (P = 0.02), I² = 81.9% factors secreted by BMCs, differentiation of BMCs into cardiac cells, and activation of cardiac stem cells have all been suggested. 73, 74 The Sustained Nature of Benefits
Mean
We performed additional analyses based on duration of follow-up to examine whether the benefits would persist during long-term follow-up. As shown in Table 4 , the improvement in LVEF was robust even beyond 24 months, whereas the reduction in infarct size and LV volumes persisted for at least Ͼ12 months. These data indicate that the benefits of BMC transplantation on LV structure and function are not transient.
Patient Characteristics
Notwithstanding this uncertainty about mechanisms, we analyzed data on the basis of predefined subgroups, attempting to identify the potential factors that may influence the observed benefits. When analyzed in terms of the type of IHD, BMC transplantation in patients with chronic IHD produced greater reduction in LVESV compared with acute MI patients who received BMC therapy (Table 5) . These findings indicate that beyond the acute setting, BMC transplantation can also effectively ameliorate LV remodeling, which is a chronic process. Further analysis revealed similar benefits regardless of the location of MI, although the reduction in LVEDV was more pronounced in patients with anterior MI. Analysis based on the median LVEF (43%) in recipients showed significantly greater reduction in LV volumes in patients with LVEF Ͻ43% at baseline (Table 5 ). These differences in outcomes persisted when subgroup data were analyzed using a baseline LVEF of 50%, below which LV dysfunction is considered present. Importantly, BMC therapy failed to reduce LVEDV in patients with a baseline LVEF Ն43% (Table 5 ). Together, these results indicate that LV remodeling outcomes are superior with lower baseline LVEF in recipients. Although no rigid cutoff value below which BMC transplantation would be ineffective could be determined, these data indicate that the benefits of BMC transplantation are greater in recipients with LV dysfunction at baseline.
Timing of Cell Injection
After an acute MI, the initial inflammatory myocardial milieu progressively changes to that of a remodeled heart, and understandably, the fate of injected BMCs and the outcomes of therapy may depend on the timing of cell injection. Interestingly, when BMCs were injected Ͻ7 days (the median interval) after acute MI and/or percutaneous coronary intervention, the improvements in LVEF, infarct scar size, and LVESV were similar to those when BMC injection within the 7-to 30-day period; however, improvement in LVEDV was absent with delayed BMC injection (Table 5) . These results underscore the critical need for direct comparison of different timings of cell therapy after acute MI in prospective trials.
The Impact of Cell Number
Because only a small fraction of injected cells are retained in the myocardium, the total number of BMCs injected may determine the degree of cardiac recovery. Although the mean changes in LVEF, infarct size, and LVEDV were similar in patients who received Ն100ϫ10
6 BMCs (the median number in included studies) and Ͻ100ϫ10 6 BMCs, there was a greater reduction in LVESV in patients who received Ͻ100ϫ10 6 BMCs. On further analysis with progressively lower BMC numbers, none of the benefits (improvement in LVEF and reduction in infarct size, LVESV, and LVEDV) were observed in patients who received Ͻ40ϫ10 6 BMCs, whereas improvements in all 4 outcome parameters were evident in those who received Ն40ϫ10 6 cells (Table 5 ). However, a limitation in this type of subgroup analysis is the fact that these trials did not directly compare the effects of low and high doses of BMC transplantation. Moreover, clinical factors such as the timing after MI and the route of injection may also be responsible for the lack of benefits observed with lower number of BMCs.
Comparison of Cell Types
Since the initial demonstration of cardiac repair with Lin-/ckit ϩ BMCs, a number of other BMC subfractions have been used for similar purposes. In a subgroup analysis, BMMNC transplantation resulted in improvement in all 4 primary outcomes, whereas therapy with CD133 ϩ and/or CD34 ϩ cells did not improve LVEF, scar size, or volumes (Table 5) . While this finding could be related to the small number of studies (reduced sample size) with these subsets, the benefits of specific subgroups of BMMNCs need further evaluation.
It is important to note that recent studies have documented the efficacy of myocardial repair with various adult cells from other tissues, including the heart. Indeed, the c-kit ϩ cardiac stem cells 75 are considered optimally suited for myocardial repair because of their cardiac origin and inherent ability to differentiate into cardiac lineages. Consistent with the efficacy of cardiac stem cells to repair infarcted myocardial tissue after intravascular delivery 76 and in the setting of an old MI, 77 intracoronary delivery of autologous cardiac stem cells improved LVEF by 12.3% and reduced infarct size by 30% after 1 year in patients with ischemic cardiomyopathy in a recent trial. 78 In a subsequent study, 79 intracoronary injection of cardiosphere-derived cells reduced infarct mass and improved regional myocardial contractility in patients with acute MI and LV dysfunction. Thus, the efficacy of cardiac stem cells for cardiac repair needs to be compared with BMMNCs in future trials.
The Importance of Cell Processing Methods
It has been appropriately suggested that cell processing methods affect outcomes. 80 , 81 Therefore, we performed a 
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subgroup analysis based on the specific method of densitygradient centrifugation, and the benefits were comparable with Lymphoprep and with other Ficoll-based protocols (Table 5 ). Additional subgroup analysis showed greater improvement in LVEF and LVESV with the use of heparin in the final BMC suspension (Table 5) . Importantly, BMCs were stored for various lengths of time, and further studies are necessary to directly assess the importance of additional factors in this process.
Route of Injection
In patients with acute MI, all of the included studies used the intracoronary route. Therefore, we analyzed the impact of cell delivery approaches in patients with chronic IHD only. There was no significant difference between outcomes with intracoronary compared with intramyocardial administration in patients with CIHD (Table 5) . Nonetheless, in clinical scenarios, the applicability and selection of intracoronary and intramyocardial routes will often depend on patient characteristics and logistics. 
Improvement in Survival and Adverse Outcomes During Follow-Up
With the growing number of cell therapy trials, it has become critically important to consider the overall clinical picture, which includes broader end points. In this light, and although analyzed as secondary outcomes, the ability of BMC transplantation to reduce all-cause and cardiac mortalities, incidence of recurrent MI, and stent thrombosis is noteworthy. The incidence of heart failure and cerebrovascular accident also showed a trend toward reduction. These data suggest that BMC transplantation may modulate other as-yet unknown variables that may influence the overall outcomes positively.
The Impact of Imaging Modality
The potential influence of imaging modality was analyzed for all primary outcomes. Interestingly, the improvements in LV functional parameters were more pronounced in studies that used echocardiography or LVG compared with those using MRI. It is important to note that the differences in mean change by MRI were uniformly directionally concordant with other modalities, albeit not statistically significant. Thus, these results need to be interpreted in light of the relative paucity of studies that have used MRI for the assessment of primary outcomes (Table 1 ). The increasing use of MRI in newer studies may provide additional data for effective comparison among various imaging modalities.
Safety
Our review demonstrates that BMC transplantation is safe in patients with IHD. The incidence of in-stent restenosis, a potential concern in patients treated with intracoronary BMC injection, was similar in BMC-treated and control patients. The incidence of other important clinical adverse outcomes, including target vessel revascularization and ventricular arrhythmia, also did not differ between groups.
The Selection of Outcome Variables
In this systematic review, we were able to analyze the primary variables that were reported in a majority of studies. However, it is important to note that these variables have inherent limitations in serving as accurate end points of BMC therapy. For example, LVEF is known to be load dependent and may be influenced by hypercontractile segments in the viable myocardium. Furthermore, its prognostic significance diminishes with values Ͼ45%. Therefore, in future studies, it will be important to identify a combinatorial set of parameters that will reliably reflect the true impact of BMC therapy in patients with IHD.
Limitations
The degree of heterogeneity observed among trials in this review is a limitation. This heterogeneity may have resulted from the differences in imaging modalities used to determine LV volumes and LVEF, BMC number and processing, timing and route of injection, and differences in baseline characteristics among the study populations. We conducted predetermined subgroup analyses for the mode of imaging, timing of BMC injection, and number of BMCs injected. However, a limitation in subgroup analysis, although predefined, is that the number of studies included in 1 subgroup may be less than the other(s). This could lead to a smaller sample size, which may result in nonsignificant association. Nonetheless, the improvements observed across most of these subgroups (Tables 4, 5 , and 7) suggest that the associations are likely valid. Sensitivity analyses based on sample size, baseline LVEF, and route of injection also did not explain the heterogeneity. Most of these studies were conducted in small patient populations with a few exceptions and did not focus on broad clinical outcomes.
Conclusions
The results of our systematic review suggest that BMC transplantation in addition to standard therapy in patients with IHD improves LV function and remodeling and patientimportant clinical outcomes. Further large-scale randomized studies are needed to critically evaluate the multifaceted benefits of this promising therapeutic approach. 
CLINICAL PERSPECTIVE
Although adult bone marrow cell (BMC) therapy for cardiac repair appears promising, divergent data from smaller clinical trials have generated lingering controversy over the nature and extent of benefits. We performed a systematic review and meta-analysis of pooled data from 50 trials to assess the impact of BMC therapy on clinically important end points. Our results show that BMC therapy modestly improves left ventricular function and remodeling in patients with ischemic heart disease and that these benefits persist during long-term follow-up. These data also suggest that BMC therapy is associated with reduced all-cause and cardiac mortality and reduced incidence of recurrent myocardial infarction and stent thrombosis without any significant increase in adverse events. BMC therapy seems effective for both acute myocardial infarction and chronic ischemic cardiomyopathy, largely independently of the location of myocardial infarction. Patients with lower left ventricular ejection fraction at baseline appear to benefit more. To be effective, injection of at least 40 million BMCs seems necessary, and the remodeling benefits seem more pronounced with earlier BMC injection. Although BM mononuclear cells are generally more effective compared with subpopulations, cell processing techniques deserve particular attention because they influence the outcomes significantly. Finally, the magnitude of changes in various outcome parameters depends on the imaging modality, although the findings remain directionally concordant. Thus, larger clinical trials using stringent methodology and a broader array of outcomes are warranted to definitively determine the true utility of this novel therapeutic strategy for cardiac repair. . These benefits were noted regardless of the study design (randomized controlled study versus cohort study) and the type of ischemic heart disease (acute myocardial infarction versus chronic ischemic heart disease) and persisted during long-term follow-up. Importantly, all-cause mortality, cardiac mortality, and the incidence of recurrent myocardial infarction and stent thrombosis were significantly lower in BMC-treated patients compared with control subjects.
Conclusions-Transplantation of adult BMCs improves LV function, infarct size, and remodeling in patients with ischemic
heart disease compared with standard therapy, and these benefits persist during long-term follow-up. BMC transplantation also reduces the incidence of death, recurrent myocardial infarction, and stent thrombosis in patients with ischemic heart disease. (Circulation. 2012;126:551-568.)
Key Words: bone marrow cells � myocardial infarction � myocardial ischemia � stem cells � ventricular remodeling C oronary artery disease and myocardial infarction (MI) cause significant mortality, morbidity, and economic burden. 1 Despite current medical and interventional therapies, myocardial tissue lost during MI is replaced by noncontractile scar followed by remodeling of the left ventricle (LV) and gradual progression to heart failure. Based on promising results from preclinical studies and clinical trials, a new therapeutic approach-transplantation of adult bone marrowderived cells (BMCs) for heart repair-has gained vigorous momentum over the past decade. However, although BMC injection resulted in significant improvement in LV function and structure in many studies, 2,3 these benefits were mixed or absent in several others. 4 -8 Although results from clinical trials and meta-analyses have documented that BMC transplantation is feasible and safe, 7 the efficacy of this approach for cardiac repair continues to remain unclear and controversial. In addition, the long-term persistence of benefits of BMC transplantation remains uncertain. 9 
Clinical Perspective on p
Because of the relatively small number of patients even in pooled data sets, 7,10 satisfactory analysis of several key aspects of outcomes could not be achieved previously. These include the impact of BMC transplantation on long-term patient-important clinical outcomes and the persistence of benefits during prolonged follow-up. Although surrogate end points demonstrate benefit with BMC transplantation, 7 understanding the clinical impact of this new therapy on hard clinical 
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end points is quintessential before mainstream application. With the reporting of several newer clinical trials 5, 6, since our prior review, we sought to systematically review the effects of adult BMC transplantation in patients with ischemic heart disease (IHD) on clinical and surrogate end points.
Methods
Search Strategy
We searched MEDLINE, the Web of Science, the Cochrane Central Register of Controlled Trials, and the reference lists of retrieved reports through January 2012 for studies of BMC transplantation in patients with IHD using the following terms: "stem cells," "progenitor cells," "bone marrow cells," "coronary artery disease," "myocardial infarction," "acute myocardial infarction," "ischemic cardiomyopathy," "cardiomyopathy," and "heart failure." The complete search strategy is provided in Appendix I in the online-only Data Supplement.
Study Selection
Studies were included if they were (1) randomized controlled trials or cohort studies with a control group, (2) conducted in patients with acute myocardial MI or chronic IHD, (3) conducted in patients who received percutaneous coronary intervention or thrombolysis or coronary artery bypass surgery, and (4) designed so that patients in the intervention arm received BMC therapy via either intracoronary injection or intramyocardial injection and patients in the control arm received standard therapy. Studies that had at least 1 month of follow-up and �10 patients as the total sample size were included. Because we used mean and standard deviation, studies that reported data using median and range could not be included. Search criteria were set to include only human studies conducted in adults �18 years of age. Studies that used circulating progenitor cells after granulocyte colony-stimulating factor mobilization were excluded to avoid confounding direct effects of granulocyte colony-stimulating factor on the myocardium and BMCs. Studies that did not report preintervention and postintervention outcomes of interest were excluded. Studies published in languages other than English were excluded except those for which abstracts were available in English.
Data Extraction
Quality Assessment
Data Analysis
Statistical analyses were performed with Cochrane RevMan version 5, and results were expressed as weighted mean differences for continuous outcomes with 95% confidence intervals (CIs). Data were pooled by use of the DerSimonian-Laird random-effects model, but a fixed-effects model was also used to ensure the robustness of the model chosen and the susceptibility to outliers. Heterogeneity was analyzed with the I 2 statistic, with a significance level of ��0.05. For the I 2 statistic, heterogeneity was defined as low (25%-50%), moderate (50%-75%), or high (�75%). We planned to conduct sensitivity analysis if significant heterogeneity was found (I 2 �50%) for any one of the outcomes. For studies that reported mean�SD at baseline and follow-up but did not report the actual change (from baseline to follow-up) as mean�SD, the change in SD was calculated with a standardized formula previously used to calculate changes in mean and standard deviation. 52 The Peto odds ratio (OR) was calculated for clinical outcomes (all-cause mortality, cardiac mortality, recurrent MI, stent thrombosis, heart failure, in-stent restenosis, target vessel revascularization, cerebrovascular event, and ventricular arrhythmias).
Subgroup Analysis and Sensitivity Analysis
Planned subgroup analyses were conducted based on (1) type of study design (RCT versus cohort study); (2) type of IHD (acute MI versus chronic IHD); (3) duration of follow-up; (4) baseline LVEF of �43% versus �43% (43% was the median LVEF at baseline in included studies) and �50% versus �50% (LVEF �50% represents LV dysfunction); (5) 
Results
Search Results
The initial search retrieved 1724 reports, of which 1544 were excluded on the basis of the title and abstract. After the exclusion of 36 review articles and 5 reports of ongoing trials, full-text analysis was performed on 139 reports, of which 89 were excluded because of unrelated outcomes and the use of granulocyte colony-stimulating factor and circulating progenitor cells. The remaining 50 studies (36 RCTs and 14 cohort studies enrolling a total of 2625 patients) 2-6,9,11-48,53-70 that reported changes in LVEF, infarct size, LVESV, or LVEDV in patients who underwent BMC transplantation compared with standard therapy were included in the final analysis (Figure 1 ). Table 1 summarizes the characteristics of included studies. The median follow-up duration was 6 months (range, 3-60 months), and the median sample size was 39 patients (range, 10 -391 patients). The timing of BMC transplantation in patients with acute MI varied among the included studies (median, 6.7 days; range, 1 to 18.4 days), and the median number of BMCs injected was 100�10 6 (range, 2�10
Study Characteristics
Study Quality
The quality metrics of included RCTs are shown in Table 2, and  Table 3 summarizes the quality of cohort studies. All cohort studies and at least 15 RCTs failed to blind participants and/or caregivers; 7 RCTs did not provide adequate information on blinding of participants and caregivers; and blinding of outcome assessors was unclear in at least 3 RCTs. The loss and adequacy of follow-up in the eligible studies are provided in Tables 2 and  3 . The follow-up was complete in most studies with shorter follow-up duration. In studies with longer follow-up, the percent of patients lost to follow-up was acceptable. The inter-reviewer agreement on these quality domains was �90%.
Cardiac Parameters
Compared with the standard treatment group, BMC transplantation improved LVEF by 3.96% (95% CI, 2.90 -5.02; P�0.00001; Figure 2 ), reduced infarct size by 4.03% (95% CI, �5.47 to �2.59; P�0.00001; Figure 3) , reduced LVESV by 8.9 mL (95% CI, �11.5 to �6.25; P�0.00001; Figure 4) , and reduced LVEDV by 5.23 mL (95% CI, �7.6 to �2.86; P�0.0001; Figure 5 ).
Persistence of Benefits During Long-Term Follow-Up
With analyses based on the duration of follow-up, the improvement in LVEF persisted for at least �24 months, and 
Subgroup Analysis
Subgroup analysis showed that improvements in LV function, scar size, and LV volumes were significant regardless of the type of IHD (acute MI versus chronic IHD), except that BMC transplantation produced a greater reduction in LVESV in patients with chronic IHD (Table 5 ). The benefits of BMC therapy were similar in patients with MI in any territory compared with those with anterior MI, although improvement in LVEDV was greater in the latter (Table 5 ). The impact of baseline LVEF was analyzed separately on the basis of the median LVEF (43%) and the presence of LV systolic dysfunction (LVEF �50%). Results from both analyses showed that recipients of BMC transplantation with lower LVEF at baseline experienced significantly greater improvement in LVESV and LVEDV, with no significant reduction in LVEDV in recipients with baseline LVEF �43% and �50% (Table 5 ). In patients with acute MI, BMC injection �7 days after acute MI and/or percutaneous coronary intervention produced similar improvements in EF, scar size, and LVESV compared with BMC injection between 7 and 30 days. The improvement in LVEDV was also significant when cells were 12 injected at �7 days, whereas BMC injection between 7 and 30 days failed to reduce LVEDV (Table 5) . Analysis based on the median BMC number (100�10 6 ) showed that injection of �100�10 6 BMCs produced similar improvements in LVEF, scar size, and LVEDV compared with �100�10
6 BMCs, whereas reduction in LVESV was significantly greater with �100�10 6 BMCs. Additional analyses using progressively lower BMC numbers showed that injection of �40�10 6 BMCs resulted in significant improvement in all 4 primary outcome measures (LVEF, scar size, LVESV, and LVEDV), whereas injection of �40�10
6
BMCs did not show improvement in any outcome ( Table 5 ), indicating that 40�10 6 BMCs may represent the cutoff below which BMCs fail to exert a majority of the desired benefits.
In terms of cell types, 36 studies used BMMNCs, 5 studies used BMCs, 6 studies used CD133
� and/or CD34 � cells, and 3 studies used mesenchymal stem cells and/or endothelial progenitor cells. Subgroup analysis showed that although BMMNC therapy improved LVEF, scar size, and LV volumes, the pooled effects of CD133 � and/or CD34 � cell therapy were not significantly different compared with control subjects (Table 5 ). The reduction in scar size with BMMNC therapy was significantly greater compared with CD133 � /CD34 � cells. Analysis based on the methods of cell preparation showed similar benefits in LVEF, scar size, and LVESV when cells were isolated with Lymphoprep compared with other Ficoll-based methods (Table 5 ). Further subgroup analysis comparing studies that used heparinized saline versus saline-based solutions without heparin in the final cell suspension showed greater improvement in LVEF and LVESV with heparinized saline, whereas improvements in scar size and LVEDV were comparable with both methods (Table 5) . In 26 studies, cells were injected on the same day as BM harvest, and in 9 studies, cells were injected by the next day (Table 1 ). BMCs were cultured or cell injection was delayed for up to 48 hours in 4 studies, and the time frame was unclear in 11. Because information on storage condition, especially temperature during storage, was not available in the vast majority, subgroup analysis was not performed.
In terms of the route of injection, all patients with acute MI received intracoronary injection of BMCs. Therefore, the impact of intracoronary versus intramyocardial route of injection was analyzed in patients with chronic IHD. In these patients, the outcomes were not significantly different between the 2 routes of BMC administration (Table 5) . With regard to the design of included studies, the benefits remained significant when RCTs and cohort studies were analyzed separately (Figures 2-5) , albeit with greater magnitudes in cohort studies compared with RCTs (Table 5) .
Impact of BMC Therapy on Survival and Clinical Outcomes
Compared with patients who received standard therapy, BMC-treated patients experienced significant decrease in all-cause mortality (OR, 0.39; 95% CI, 0.27-0. 55 (1) representativeness of the exposed cohort: A, truly representative of the average patient with ischemic heart disease; B, somewhat representative of the average patient with ischemic heart disease; C, selected group; and D, no description of the derivation of the cohort. (2) Selection of the nonexposed cohort: A, drawn from the same community as the exposed cohort; B, drawn from a different source; and C, no description of the derivation of the nonexposed cohort. follow-up, all subjects accounted for; B, subjects lost to follow-up unlikely to introduce bias (small number lost), follow-up rate �90%, or description provided of those lost; C, follow-up rate �90% and no description of those lost; and D, no statement.
Total (95% CI)
Sensitivity Analysis
Heterogeneity was explored by conducting sensitivity analysis based on the route of injection, sample size, median LVEF, and median number of BMCs injected. All clinical trials in patients with acute MI used the intracoronary route for BMC injection. Analysis based on the route of injection, median LVEF, and median number of BMCs did not explain the heterogeneity (Table 5) . Analysis of studies based on sample size (�50 versus �50 patients) did not change the results and did not explain the heterogeneity.
Publication Bias
Discussion Salient Findings
Our meta-analysis of pooled data from 2625 patients, the largest to date, demonstrates that adult BMC transplantation results in modest yet significant improvements in LVEF, infarct scar size, LVESV, and LVEDV. These results indicate that BMC transplantation can improve LV function and remodeling beyond the improvements achievable with standard therapy. The persistence of LVEF improvement at least beyond 24 months and other enhancements at least beyond 12 months underscores the long-standing nature of cardiac repair induced by BMC transplantation. Importantly, and although assessed as secondary outcomes, our results also indicate that BMC-treated patients experienced significant reduction in all-cause mortality, cardiac mortality, recurrent MI, and stent thrombosis compared with patients who received standard therapy. Although the clinical trials included in this metaanalysis were not designed to assess the impact of BMC transplantation on long-term clinical outcomes as their primary outcome, these findings are highly significant from a 
Total (95% CI)
Heterogeneity: Tau² = 37.02; Chi² = 188.32, df = 35 (P < 0.00001); I² = 81% Test for overall effect: Z = 6.56 (P < 0.00001) Test for subgroup differences: Chi² = 5.51, df = 1 (P = 0.02), I² = 81.9% findings indicate that beyond the acute setting, BMC transplantation can also effectively ameliorate LV remodeling, which is a chronic process. Further analysis revealed similar benefits regardless of the location of MI, although the reduction in LVEDV was more pronounced in patients with anterior MI. Analysis based on the median LVEF (43%) in recipients showed significantly greater reduction in LV volumes in patients with LVEF �43% at baseline (Table 5 ). These differences in outcomes persisted when subgroup data were analyzed using a baseline LVEF of 50%, below which LV dysfunction is considered present. Importantly, BMC therapy failed to reduce LVEDV in patients with a baseline LVEF �43% (Table 5) . Together, these results indicate that LV remodeling outcomes are superior with lower baseline LVEF in recipients. Although no rigid cutoff value below which BMC transplantation would be ineffective could be determined, these data indicate that the benefits of BMC transplantation are greater in recipients with LV dysfunction at baseline.
Mean
Timing of Cell Injection
After an acute MI, the initial inflammatory myocardial milieu progressively changes to that of a remodeled heart, and understandably, the fate of injected BMCs and the outcomes of therapy may depend on the timing of cell injection. Interestingly, when BMCs were injected �7 days (the median interval) after acute MI and/or percutaneous coronary intervention, the improvements in LVEF, infarct scar size, and LVESV were similar to those when BMC injection within the 7-to 30-day period; however, improvement in LVEDV was absent with delayed BMC injection (Table 5) . These results underscore the critical need for direct comparison of different timings of cell therapy after acute MI in prospective trials.
The Impact of Cell Number
Because only a small fraction of injected cells are retained in the myocardium, the total number of BMCs injected may determine the degree of cardiac recovery. Although the mean changes in LVEF, infarct size, and LVEDV were similar in patients who received �100�10
6 BMCs (the median number in included studies) and �100�10 6 BMCs, there was a greater reduction in LVESV in patients who received �100�10 6 BMCs. On further analysis with progressively lower BMC numbers, none of the benefits (improvement in LVEF and reduction in infarct size, LVESV, and LVEDV) were observed in patients who received �40�10 6 BMCs, whereas improvements in all 4 outcome parameters were evident in those who received �40�10 6 cells (Table 5 ). However, a limitation in this type of subgroup analysis is the fact that these trials did not directly compare the effects of low and high doses of BMC transplantation. Moreover, clinical factors such as the timing after MI and the route of injection may also be responsible for the lack of benefits observed with lower number of BMCs.
Comparison of Cell Types
Since the initial demonstration of cardiac repair with Lin-/ckit � BMCs, a number of other BMC subfractions have been used for similar purposes. In a subgroup analysis, BMMNC transplantation resulted in improvement in all 4 primary outcomes, whereas therapy with CD133 � and/or CD34 � cells did not improve LVEF, scar size, or volumes (Table 5) . While this finding could be related to the small number of studies (reduced sample size) with these subsets, the benefits of specific subgroups of BMMNCs need further evaluation.
It is important to note that recent studies have documented the efficacy of myocardial repair with various adult cells from other tissues, including the heart. Indeed, the c-kit � cardiac stem cells 75 are considered optimally suited for myocardial repair because of their cardiac origin and inherent ability to differentiate into cardiac lineages. Consistent with the efficacy of cardiac stem cells to repair infarcted myocardial tissue after intravascular delivery 76 and in the setting of an old MI, 77 intracoronary delivery of autologous cardiac stem cells improved LVEF by 12.3% and reduced infarct size by 30% after 1 year in patients with ischemic cardiomyopathy in a recent trial. 78 In a subsequent study, 79 intracoronary injection of cardiosphere-derived cells reduced infarct mass and improved regional myocardial contractility in patients with acute MI and LV dysfunction. Thus, the efficacy of cardiac stem cells for cardiac repair needs to be compared with BMMNCs in future trials.
The Importance of Cell Processing Methods
It has been appropriately suggested that cell processing methods affect outcomes. 80, 81 Therefore, we performed a 
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Route of Injection
Improvement in Survival and Adverse Outcomes During Follow-Up
The Impact of Imaging Modality
Safety
The Selection of Outcome Variables
In this systematic review, we were able to analyze the primary variables that were reported in a majority of studies. However, it is important to note that these variables have inherent limitations in serving as accurate end points of BMC therapy. For example, LVEF is known to be load dependent and may be influenced by hypercontractile segments in the viable myocardium. Furthermore, its prognostic significance diminishes with values �45%. Therefore, in future studies, it will be important to identify a combinatorial set of parameters that will reliably reflect the true impact of BMC therapy in patients with IHD.
Limitations
Conclusions
The results of our systematic review suggest that BMC transplantation in addition to standard therapy in patients with IHD improves LV function and remodeling and patientimportant clinical outcomes. Further large-scale randomized studies are needed to critically evaluate the multifaceted benefits of this promising therapeutic approach.
